Evidence map›Paper›PMID 25820757›Full record

ArticleHepatology (Baltimore, Md.)2015

Salivary microbiota reflects changes in gut microbiota in cirrhosis with hepatic encephalopathy.

Jasmohan S Bajaj, Naga S Betrapally, Phillip B Hylemon, Douglas M Heuman, Kalyani Daita, Melanie B White, Ariel Unser, Leroy R Thacker, Arun J Sanyal, Dae Joong Kang and 2 more

3 registry-linked trialsAbstract read
In one paragraph

Article in Hepatology (Baltimore, Md.), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 184 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
184citing papers in PubMed, 2 pooled it
12.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03279224 phase2 / phase3unknown statusnot on this mapstarted 2018, after this paper: background citation

A Randomized Controlled Trial of the Safety and Efficacy of Fecal Microbiota Transplantation in a Population With Bipolar Disorder

TypeinterventionalSponsorValerie TaylorRan2018 to 2022Enrolled35ConditionsBipolar DepressionArmsAllogenic FMT, Autologous FMT
NCT04543643 phase3unknown statusnot on this mapstarted 2021, after this paper: background citation

Endoscopic and Microbiological Assessment of the Effect of Carvedilol Combined With Berberine on GOV in Cirrhosis: a Prospective Cohort Study

TypeinterventionalSponsorTianjin Second People's HospitalRan2021 to 2023Enrolled288ConditionsCirrhosis Due to Hepatitis B, Cirrhosis Due to Hepatitis C, Gastroesophageal VaricesArmsCarvedilol, Berberine
NCT04861571 naactive not recruitingnot on this mapstarted 2023, after this paper: background citation

Effect of Very Low-calorie Diet on the Reduction of Liver Steatosis and Fibrosis in Subjects With Obesity and Non-alcoholic Fatty Liver Disease

TypeinterventionalSponsorUniversity of IowaRan2023 to 2026Enrolled20ConditionsNAFLDArmsDietary intervention with very low calorie diet (VLCD), Control Arm
3 · Its place in the literature

Who cites it

184 citing papers in PubMed, 2 syntheses or guidelines pooled it, 320 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Oral Microbiome Characteristics in Patients With Autoimmune Hepatitis.Frontiers in cellular and infection microbiology · 2021
    Trial
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Microbial Approaches to Treat and Prevent Hepatic Encephalopathy.Gastroenterology clinics of North America · 2025
    Review
  20. Review

124 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

12 authors at 3 institutions in 1 country.

Jasmohan S BajajDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Naga S BetrapallyMicrobiome Analysis Center, George Mason University, Manassas, VA.
Phillip B HylemonDepartment of Microbiology, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Douglas M HeumanDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Kalyani DaitaDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Melanie B WhiteDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Ariel UnserDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Leroy R ThackerDepartment of Biostatistics, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Arun J SanyalDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Dae Joong KangDivision of Gastroenterology, Hepatology and Nutrition, Virginia Commonwealth University and McGuire VA Medical Center, Richmond, VA.
Masoumeh SikaroodiMicrobiome Analysis Center, George Mason University, Manassas, VA.
Patrick M GillevetMicrobiome Analysis Center, George Mason University, Manassas, VA.
Virginia Commonwealth University · USGeorge Mason University · USHunter Holmes McGuire VA Medical Center · US

Funding

Spectrum of Neuro-Cognitive Impairment in CirrhosisR01DK087913 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S · 2011 to 2015
$2.0M
Hepatic Encephalopathy in Alcoholic Cirrhosis: A Systems Biology ApproachR01AA020203 · NIAAA · VIRGINIA COMMONWEALTH UNIVERSITY · PI BAJAJ, JASMOHAN S · 2010 to 2012
$1.0M
Fecal Microbiota Transplant in Veterans with CirrhosisI01CX001076 · VA · VA VETERANS ADMINISTRATION HOSPITAL · PI BAJAJ, JASMOHAN S · 2015 to 2024
–
CSRD VA I01 CX001076NIAAA NIH HHS R01 AA020203NIAAA NIH HHS R01AA020203NIDDK NIH HHS R01 DK087913NIDDK NIH HHS R01DK087913
6 · The paper itself

Abstract

unlabelledAltered gut microbiome is associated with systemic inflammation and cirrhosis decompensation. However, the correlation of the oral microbiome with inflammation in cirrhosis is unclear. Our aim was to evaluate the oral microbiome in cirrhosis and compare with stool microbiome. Outpatients with cirrhosis (with/without hepatic encephalopathy [HE]) and controls underwent stool/saliva microbiome analysis (for composition and function) and also systemic inflammatory evaluation. Ninety-day liver-related hospitalizations were recorded. Salivary inflammation was studied using T helper 1 cytokines/secretory immunoglobulin A (IgA), histatins and lysozyme in a subsequent group. A total of 102 patients with cirrhosis (43 previous HE) and 32 age-matched controls were included. On principal component analysis (PCA), stool and saliva microbiome clustered far apart, showing differences between sites as a whole. In salivary microbiome, with previous HE, relative abundance of autochthonous families decreased whereas potentially pathogenic ones (Enterobacteriaceae, Enterococcaceae) increased in saliva. Endotoxin-related predicted functions were significantly higher in cirrhotic saliva. In stool microbiome, relative autochthonous taxa abundance reduced in previous HE, along with increased Enterobacteriaceae and Enterococcaceae. Cirrhotic stool microbiota demonstrated a significantly higher correlation with systemic inflammation, compared to saliva microbiota, on correlation networks. Thirty-eight patients were hospitalized within 90 days. Their salivary dysbiosis was significantly worse and predicted this outcome independent of cirrhosis severity. Salivary inflammation was studied in an additional 86 age-matched subjects (43 controls/43 patients with cirrhosis); significantly higher interleukin (IL)-6/IL-1β, secretory IgA, and lower lysozyme, and histatins 1 and 5 were found in patients with cirrhosis, compared to controls.

conclusionsDysbiosis, represented by reduction in autochthonous bacteria, is present in both saliva and stool in patients with cirrhosis, compared to controls. Patients with cirrhosis have impaired salivary defenses and worse inflammation. Salivary dysbiosis was greater in patients with cirrhosis who developed 90-day hospitalizations. These findings could represent a global mucosal-immune interface change in cirrhosis.

Indexed as

Gastrointestinal MicrobiomeDysbiosisFecesFemaleHepatic EncephalopathyHumansInflammationIntestinesLiver CirrhosisMaleMicrobiotaMiddle AgedSaliva

Identifiers

PMID25820757
PMCPMC4587995
OpenAlexW1518286619

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.